Karyopharm Therapeutics (NASDAQ:KPTI) Posts Quarterly Earnings Results, Beats Estimates By $0.21 EPS

Karyopharm Therapeutics (NASDAQ:KPTI) announced its earnings results on Thursday. The company reported ($1.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.45) by $0.21, FiscalAI reports. The business had revenue of $35.07 million for the quarter, compared to analyst estimates of $31.40 million.

Here are the key takeaways from Karyopharm Therapeutics’ conference call:

• Karyopharm said its phase III SENTRY trial in myelofibrosis met the main spleen response endpoint, with SVR35 at week 24 of 50% versus 28% for ruxolitinib alone and no new safety signals.
• The company highlighted an encouraging overall survival signal in SENTRY, along with early variant allele frequency reductions that it believes may suggest disease-modifying activity.
• XPORT-EC-042 in endometrial cancer has completed enrollment, and Karyopharm still expects top-line data in mid-2026 for the biomarker-driven maintenance study.
• Management argued that its endometrial cancer program targets a large subgroup of TP53 wild-type, MMR-proficient patients and emphasized that the 60 mg weekly selinexor dose with mandated antiemetics should improve tolerability versus earlier studies.
• First-quarter revenue rose to $35.1 million from $30.0 million a year ago, but management said underlying XPOVIO demand fell versus last year due to new competition; it reaffirmed full-year 2026 revenue and expense guidance and said liquidity should last into late Q3 2026.

Karyopharm Therapeutics Stock Down 13.8%

Shares of KPTI opened at $7.67 on Friday. The firm’s fifty day moving average is $7.88 and its two-hundred day moving average is $7.26. The stock has a market cap of $172.96 million, a PE ratio of -0.51 and a beta of 0.80. Karyopharm Therapeutics has a 52-week low of $3.65 and a 52-week high of $10.99.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. Rodman & Renshaw raised Karyopharm Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 10th. Cantor Fitzgerald initiated coverage on Karyopharm Therapeutics in a research report on Thursday, February 5th. They issued an “overweight” rating on the stock. HC Wainwright boosted their price objective on Karyopharm Therapeutics from $8.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Piper Sandler reissued an “overweight” rating and issued a $16.00 price objective (up from $8.00) on shares of Karyopharm Therapeutics in a report on Monday, April 27th. Finally, Robert W. Baird reduced their price target on Karyopharm Therapeutics from $21.00 to $15.00 and set an “outperform” rating for the company in a report on Wednesday, March 25th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Karyopharm Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.17.

Institutional Investors Weigh In On Karyopharm Therapeutics

A number of large investors have recently made changes to their positions in the stock. T. Rowe Price Investment Management Inc. grew its position in shares of Karyopharm Therapeutics by 112.8% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,491,409 shares of the company’s stock valued at $10,977,000 after purchasing an additional 790,417 shares in the last quarter. Ikarian Capital LLC grew its position in Karyopharm Therapeutics by 1,897.9% in the fourth quarter. Ikarian Capital LLC now owns 544,554 shares of the company’s stock worth $4,008,000 after acquiring an additional 517,297 shares during the period. Geode Capital Management LLC grew its position in Karyopharm Therapeutics by 101.2% in the fourth quarter. Geode Capital Management LLC now owns 187,734 shares of the company’s stock worth $1,382,000 after acquiring an additional 94,445 shares during the period. Bank of America Corp DE grew its position in Karyopharm Therapeutics by 26.8% in the second quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock worth $726,000 after acquiring an additional 35,626 shares during the period. Finally, Boothbay Fund Management LLC purchased a new position in Karyopharm Therapeutics in the fourth quarter worth approximately $1,064,000. 66.44% of the stock is currently owned by hedge funds and other institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.